CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home About What We Do Programs and Services CADTH Reimbursement Review alpelisib
Back to Programs and Services

CADTH Reimbursement Review

alpelisib

Last Updated: March 22, 2021
Result type: Reports
Project Number: PC0247-000
Product Line: Reimbursement Review

Generic Name: alpelisib

Brand Name: Piqray

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Therapeutic Area: Advanced or Metastatic Breast Cancer.

Indications: ​Piqray (alpelisib), in combination with fulvestrant, is indicated for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA- mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.

Manufacturer Requested Reimbursement Criteria1: ​Piqray (alpelisib), in combination with fulvestrant, is indicated for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA- mutated advanced or metastatic breast cancer after disease progression following a CDK4/6 inhibitors in combination with an endocrine-based regimen.

Submission Type: Initial

Tumour Type: Breast

Project Status: Pending

Call for patient/clinician input open: March 22, 2021

Call for patient/clinician input closed: May 14, 2021

Anticipated Date: April 20, 2021

Fee Schedule1: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback